| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
13636370518 |
| Email: |
shyysw007@163.com |
| Products Intro: |
Product Name:Mirvetuximab (anti-FOLR1)
CAS:1453084-36-0
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:5mg Remarks:K10693
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Mirvetuximab
CAS:1453084-36-0
Purity:95% Package:100ug;500ug;1mg
|
Mirvetuximab manufacturers
- Mirvetuximab
-
- $1280.00
-
2026-07-03
- CAS:1453084-36-0
- Purity: > 95%
- Supply Ability: 10g
|
| | Mirvetuximab Basic information |
| Product Name: | Mirvetuximab | | Synonyms: | Mirvetuximab;Mirvetuximab (DHD10402);Research Grade Mirvetuximab(DHD10402);Mirvetuximab (anti-FOLR1);M9346A;Research Grade Mirvetuximab;>95% by SDS-PAGE | | CAS: | 1453084-36-0 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Mirvetuximab Structure]() |
| | Mirvetuximab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Mirvetuximab Usage And Synthesis |
| Uses | Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research[1][2][3]. | | References | [1] Moore KN, et al. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr 1;35(10):1112-1118. DOI:10.1200/JCO.2016.69.9538
[2] Loebrich S, et al. Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical Samples. AAPS J. 2017 Jul;19(4):1223-1234. DOI:10.1208/s12248-017-0098-0
[3] Ab O, et al. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. Mol Cancer Ther. 2015 Jul;14(7):1605-13. DOI:10.1158/1535-7163.MCT-14-1095 |
| | Mirvetuximab Preparation Products And Raw materials |
|